BioArctic and Eisai announce final positive recommendation from Canada's Drug Agency supporting public reimbursement of Leqembi

Karyopharm seeks accelerated FDA approval for selinexor–ruxolitinib in myelofibrosis

Lilly to acquire Merida Biosciences in USD2.875bn deal

Harvest Integrated Research Organization signs MoU with Differentia Biotech

Ascletis Pharma Inc doses first participant in global Phase III clinical programme of ASC30

Zambon receives European Commission approval for Hopledo in Parkinson's disease

Kazia Therapeutics reports 100% clinical benefit rate in initial paxalisib breast cancer trial

SpyGlass Pharma opens new HQ in Irvine, California

AusperBio completes USD120m Series C financing to advance AHB-137

DualityBio agrees global collaboration and licensing deal with Genentech

AbbVie seeks EMA approval for subcutaneous induction of risankizumab in Crohn's disease

Natera and Angiex partner to assess AGX101 response using Signatera

AstraZeneca and Amgen report Tezspire met primary endpoints in Phase III EoE trial

ReviR Therapeutics' RTX-117 receives FDA Rare Pediatric Disease Designation for Charcot-Marie-Tooth disease

Graviton BioScience reports positive trial results for GV101 in chronic Graft versus Host Disease